Blair William & Co. IL Has $6.58 Million Position in Catalent, Inc. (NYSE:CTLT)

Blair William & Co. IL increased its position in shares of Catalent, Inc. (NYSE:CTLT) by 199.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 100,074 shares of the company’s stock after purchasing an additional 66,658 shares during the period. Blair William & Co. IL’s holdings in Catalent were worth $6,576,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in CTLT. BI Asset Management Fondsmaeglerselskab A S raised its stake in Catalent by 163.5% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 809 shares of the company’s stock worth $53,000 after purchasing an additional 502 shares in the last quarter. First Republic Investment Management Inc. raised its position in shares of Catalent by 171.7% in the 1st quarter. First Republic Investment Management Inc. now owns 104,348 shares of the company’s stock valued at $6,857,000 after buying an additional 65,940 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Catalent by 16.5% in the 1st quarter. ProShare Advisors LLC now owns 28,363 shares of the company’s stock valued at $1,864,000 after buying an additional 4,013 shares in the last quarter. RMB Capital Management LLC raised its position in shares of Catalent by 21.1% in the 1st quarter. RMB Capital Management LLC now owns 239,458 shares of the company’s stock valued at $15,735,000 after buying an additional 41,747 shares in the last quarter. Finally, Balentine LLC acquired a new position in shares of Catalent in the 1st quarter valued at approximately $299,000.

Catalent Stock Performance

Shares of CTLT stock opened at $50.20 on Friday. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.84 and a quick ratio of 1.34. The stock has a market capitalization of $9.05 billion, a PE ratio of -38.62, a PEG ratio of 5.96 and a beta of 1.22. The business’s 50 day simple moving average is $45.89 and its 200 day simple moving average is $50.38. Catalent, Inc. has a one year low of $31.45 and a one year high of $97.54.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, August 29th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.05 billion. Catalent had a net margin of 0.93% and a return on equity of 7.13%. The business’s revenue was down 15.6% compared to the same quarter last year. During the same period last year, the company posted $1.12 EPS. As a group, research analysts forecast that Catalent, Inc. will post 0.83 earnings per share for the current year.

Wall Street Analyst Weigh In

CTLT has been the topic of a number of recent analyst reports. Morgan Stanley lifted their target price on Catalent from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Wednesday. Bank of America upped their price objective on shares of Catalent from $39.00 to $46.00 and gave the stock an “underperform” rating in a research report on Thursday. TheStreet lowered shares of Catalent from a “c” rating to a “d+” rating in a research report on Monday, June 12th. Robert W. Baird boosted their target price on shares of Catalent from $35.00 to $47.00 in a research note on Tuesday, June 13th. Finally, Royal Bank of Canada boosted their target price on shares of Catalent from $51.00 to $58.00 and gave the stock an “outperform” rating in a research note on Wednesday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Catalent presently has a consensus rating of “Hold” and a consensus price target of $60.50.

Insiders Place Their Bets

In other Catalent news, insider John J. Greisch purchased 21,000 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were purchased at an average cost of $50.24 per share, for a total transaction of $1,055,040.00. Following the acquisition, the insider now owns 34,000 shares of the company’s stock, valued at $1,708,160. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, EVP Steven L. Fasman sold 817 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $44.65, for a total transaction of $36,479.05. Following the completion of the sale, the executive vice president now directly owns 73,789 shares of the company’s stock, valued at $3,294,678.85. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John J. Greisch bought 21,000 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The shares were acquired at an average cost of $50.24 per share, with a total value of $1,055,040.00. Following the completion of the transaction, the insider now owns 34,000 shares of the company’s stock, valued at $1,708,160. The disclosure for this purchase can be found here. In the last three months, insiders have sold 5,442 shares of company stock worth $247,577. Corporate insiders own 0.58% of the company’s stock.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.